High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

A secondary aim was to determine the effect of cholecalciferol on blood pressure and serum fibroblast growth factor-23 (FGF23).

Why It Was Studied

Vitamin D deficiency contributes to secondary hyperparathyroidism, which occurs early in chronic kidney disease (CKD).

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and pilot study.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Parathyroid Hormone (PTH 1-84), so expectations could not easily colour the readings.

Some participants received a placebo instead of Parathyroid Hormone (PTH 1-84), giving a reference point.

It is described as a pilot, a small early test of whether a larger Parathyroid Hormone (PTH 1-84) study would be practical.

This was a double-blind, randomized, placebo-controlled trial.

What Was Measured

Vitamin D deficiency contributes to secondary hyperparathyroidism, which occurs early in chronic kidney disease (CKD).

The subject headings attached to it are Calcifediol, Cholecalciferol, Diet, Dietary Supplements, Fibroblast Growth Factor-23, Georgia and Hospitals, Veterans.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2012 (The American journal of clinical nutrition), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.